August 10, 2017
Bactiguard saves lives by preventing healthcare associated infections. With the development in the second quarter, sales of our own product portfolio have now increased for seven consecutive quarters, based on rolling twelve-month figures. This means that more patients have access to effective and safe infection prevention. The value of delivered products increased by approx. 76 %, due to higher volumes and improved product mix. Higher license revenues contribute considerably to the increase in total revenue compared with previous year. With continued cost control, EBITDA also improved and we reached an EBITDA margin of 11 %. Marketwise, the biggest breakthrough in the quarter was the tender we won in Stockholm. New partnerships were also established for Brazil, Italy and South Africa.